Brain Pharm: Brain Pharmacology Database User: Public
SenseLab  Home Data Search Schema Login	[Data] Pathological mechanism Name Muscarinic receptor agonists and nicotine may prevent neurodegeneration in AD Description Hypothesis Nicotinic Receptor Hypothesis   show other Extracelular pathological element β-Amyloid   show other Intracelular pathological element Pathological action Inhibits   show other Process Wnt/beta-catenin signalling   show other Process action Transmitter(s) Receptor(s) Channel(s) Pharmacological Agent Nicotine   show other Pharmacological Action Protects   show other Brain region Neuron Cell model Cellular compartment PubMed ID 18652670 Citation AlzWeb Notes Abeta binds to the extracellular cysteine-rich domain of the Frizzled receptor (Fz) inhibiting Wnt/beta-catenin signaling. Cross-talk with other signaling cascades that regulate Wnt/beta-catenin signaling, including the activation of M1 muscarinic receptor and PKC, the use of Ibuprofen-ChE bi-functional compounds, PPAR alpha, gamma agonists, nicotine and some antioxidants, results in neuroprotection against Abeta. Inestrosa, N. C., & Toledo, E. M. (2008). The role of wnt signaling in neuronal dysfunction in alzheimer's disease. Molecular Neurodegeneration, 3(1), 9. Pathology Stage Question Claim Other categories referring to "Muscarinic receptor agonists and nicotine may prevent neurodegeneration in AD"   Revisions: 3 Last time: 7/30/2008 5:09:13 PM Reviewer: Pradeep Mutalik Owner: Pradeep Mutalik
	Questions, comments, problems? Email the Database Administrator This site is Copyright 2010, Yale Center for Medical Informatics